Founders Financial Securities LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 49.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,033 shares of the company’s stock after selling 10,734 shares during the period. Founders Financial Securities LLC’s holdings in Novo Nordisk A/S were worth $531,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in NVO. Geode Capital Management LLC grew its holdings in Novo Nordisk A/S by 20.6% during the first quarter. Geode Capital Management LLC now owns 28,778 shares of the company’s stock valued at $985,000 after purchasing an additional 4,910 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Novo Nordisk A/S by 24.2% in the second quarter. Bank of Montreal Can now owns 80,934 shares of the company’s stock valued at $3,470,000 after acquiring an additional 15,756 shares during the period. Kidder Stephen W bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $202,000. Boston Financial Mangement LLC boosted its position in shares of Novo Nordisk A/S by 5.1% in the second quarter. Boston Financial Mangement LLC now owns 214,146 shares of the company’s stock valued at $9,185,000 after acquiring an additional 10,415 shares during the period. Finally, NGAM Advisors L.P. boosted its position in shares of Novo Nordisk A/S by 3.0% in the second quarter. NGAM Advisors L.P. now owns 1,545,853 shares of the company’s stock valued at $66,302,000 after acquiring an additional 44,948 shares during the period. Institutional investors own 6.01% of the company’s stock.

Several equities research analysts have recently weighed in on NVO shares. BidaskClub cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Bank of America Corporation raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Wednesday, September 13th. Finally, BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $55.00.

In other news, insider Eric S. Sprott bought 50,000 shares of Novo Nordisk A/S stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $8.34 per share, with a total value of $417,000.00. 0.07% of the stock is owned by company insiders.

Shares of Novo Nordisk A/S (NYSE NVO) traded down $0.64 during mid-day trading on Monday, reaching $51.61. The company had a trading volume of 238,794 shares, compared to its average volume of 2,123,101. The company has a market capitalization of $102,470.00, a PE ratio of 22.81, a P/E/G ratio of 3.12 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $31.91 and a 52-week high of $52.32.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/founders-financial-securities-llc-has-531000-holdings-in-novo-nordisk-as-nvo/1729205.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.